ClinicalTrials.gg
CompletedNCT01254279Updated Jan 21, 2015

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

A Phase 3 interventional study of CABAZITAXEL in Prostate Cancer Metastatic, sponsored by Sanofi. Completed at 165 sites in 29 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
984
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
3rd of 46
984 · median 60
Started
2010
the only one that year
Phase 3
7 of 46
none open now
Registered
2nd of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 7 in phase 3, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in those patients who have progressed during or after docetaxel and to document the overall safety of cabazitaxel in these patients.

Please note that in each country, patient recruitment will end when cabazitaxel becomes commercially available.

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hormone Prostate Cancer (mHRPC) previously treated with a docetaxel-containing regimen
  • Disease Progression during or after docetaxel-containing regimen for mHRPC
  • Surgical or medical castration
  • (ECOG) Performance Status (PS): 0-2
  • Life-expectancy ≥3 months
  • Adequate bone marrow, liver, and renal function: Neutrophils> 1500 /mm3; > 10 g/dL; > 100 x109/L; \< ; (AST) \< 1.5xULN; SGPT (ALT) \< 1.5xULN; Creatinine \< 1.5xULN. If creatinine 1.0 - 1.5 x ULN, will be calculated according to formula and patients with creatinine clearance \< 60 mL/min should be excluded.

Exclusion criteria

Exclusion criteria:

  • Prior radiotherapy to ≥ 40% of bone marrow
  • Prior radionuclide therapy (samarium-153, strontium-89, P-32...)
  • Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment
  • Active grade ≥2 peripheral neuropathy
  • Active grade ≥2 stomatitis
  • Active infection requiring systemic antibiotic or anti-fungal medication
  • Active cancer (other than mHRPC) including prior from which the patient has been disease-free for ≤5 years (except superficial basal cell skin cancer)
  • Known brain or
  • History of severe reaction (≥grade 3) to docetaxel
  • History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs
  • History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone
  • Uncontrolled severe illness or medical condition (including uncontrolled cardiac arrhythmias, angina pectoris, hypertension or diabetes mellitus). History of congestive heart failure ( III or IV) or myocardial infarction within last 6 months is also not allowed.
  • Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5
  • Participation in a clinical trial with any drug
  • Patient with not implementing accepted and effective method of

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
984 participants (actual)

Study arms

  • Experimental
    Cabazitaxel

    Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily

    Drug: CABAZITAXEL

Interventions

  • Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous

06

What researchers measure

Primary outcomes

  1. To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen

    Time frame: Up to 30 weeks

Secondary outcomes

  1. To document safety of cabazitaxel in these patients

    Time frame: Up to 35 weeks

07

Study locations

165 sites
  • Investigational Site Number 036004
    Box Hill, 3128, Australia
  • Investigational Site Number 036020
    Campbelltown, 2560, Australia
  • Investigational Site Number 036001
    Camperdown, 2050, Australia
  • Investigational Site Number 036002
    Camperdown, 2050, Australia
  • Investigational Site Number 036011
    Douglas, 4814, Australia
  • Investigational Site Number 036019
    Nambour, 4560, Australia
  • Investigational Site Number 036023
    North Adelaide, 5006, Australia
  • Investigational Site Number 036008
    Parkville, 3050, Australia
  • Investigational Site Number 036005
    Perth, Australia
  • Investigational Site Number 036003
    Port Macquarie, Australia
  • Investigational Site Number 036025
    Randwick, 2031, Australia
  • Investigational Site Number 036009
    South Brisbane, 4101, Australia
  • Investigational Site Number 036022
    South Brisbane, 4101, Australia
  • Investigational Site Number 036017
    Southport, 4215, Australia
  • Investigational Site Number 036012
    St Leonards, 2065, Australia
  • Investigational Site Number 036010
    Sydney, 2076, Australia
  • Investigational Site Number 036013
    Sydney, Australia
  • Investigational Site Number 036014
    Sydney, Australia
  • Investigational Site Number 036016
    Tweed Heads, Australia
  • Investigational Site Number 036024
    Wendouree, 3355, Australia
  • Investigational Site Number 036007
    Westmead, 2145, Australia
  • Investigational Site Number 036015
    Wodonga, Australia
  • Investigational Site Number 040-004
    Linz, 4010, Austria
  • Investigational Site Number 040-005
    Salzburg, Austria
  • Investigational Site Number 040-003
    Vienna, Austria
  • Investigational Site Number 040-002
    Wien, 1090, Austria
  • Investigational Site Number 056002
    Brugge, 8000, Belgium
  • Investigational Site Number 056007
    Bruxelles, 1020, Belgium
  • Investigational Site Number 056003
    Haine St Paul, 7100, Belgium
  • Investigational Site Number 056005
    Liège, 4000, Belgium
  • Investigational Site Number 056004
    Ottignies, 1340, Belgium
  • Investigational Site Number 056001
    Roeselare, 8800, Belgium
  • Investigational Site Number 056006
    Tournai, 7500, Belgium
  • Investigational Site Number 070003
    Banja Luka, Bosnia and Herzegovina
  • Investigational Site Number 070001
    Sarajevo, Bosnia and Herzegovina
  • Investigational Site Number 070002
    Zenica, Bosnia and Herzegovina
  • Investigational Site Number 100004
    Plovdiv, 4000, Bulgaria
  • Investigational Site Number 100001
    Sofia, 1527, Bulgaria
  • Investigational Site Number 100003
    Sofia, 1756, Bulgaria
  • Investigational Site Number 100002
    Sofia, Bulgaria
  • Investigational Site Number 124012
    Kitchener, N2G1G3, Canada
  • Investigational Site Number 124009
    Laval, H7M3L9, Canada
  • Investigational Site Number 124004
    London, N6A 4L6, Canada
  • Investigational Site Number 124007
    Moncton, E1C6Z8, Canada
  • Investigational Site Number 124001
    Montreal, H2L 4M1, Canada
  • Investigational Site Number 124011
    Montreal, H3G1A4, Canada
  • Investigational Site Number 124010
    Quebec, G1R 2J6, Canada
  • Investigational Site Number 124003
    Toronto, M4N3M5, Canada
  • Investigational Site Number 124002
    Toronto, M5G2M9, Canada
  • Investigational Site Number 124006
    Winnipeg, R3E0V9, Canada
  • Investigational Site Number 191-001
    Zagreb, 10000, Croatia
  • Investigational Site Number 203001
    Brno, 65653, Czech Republic
  • Investigational Site Number 208-001
    Cph Ø, 2100, Denmark
  • Investigational Site Number 208-002
    Herlev, 2730, Denmark
  • Investigational Site Number 208-003
    Odense, 5000, Denmark
  • Investigational Site Number 246002
    Helsinki, 00180, Finland
  • Investigational Site Number 246001
    Seinäjoki, 60220, Finland
  • Investigational Site Number 348001
    Budapest, 1032, Hungary
  • Investigational Site Number 348002
    Szolnok, 5000, Hungary
  • Investigational Site Number 348003
    Szombathely, 9700, Hungary
  • Investigational Site Number 348004
    Veszprém, 8200, Hungary
  • Investigational Site Number 356004
    Chennai, 600035, India
  • Investigational Site Number 356006
    Gurgaon, 12201, India
  • Investigational Site Number 356001
    New Delhi, 110029, India
  • Investigational Site Number 356002
    New Delhi, 110085, India
  • Investigational Site Number 356005
    Trivandrum, 695011, India
  • Investigational Site Number 372004
    Cork, Ireland
  • Investigational Site Number 372003
    Dublin 24, Ireland
  • Investigational Site Number 372001
    Dublin 7, Ireland
  • Investigational Site Number 372002
    Dublin 7, Ireland
  • Investigational Site Number 380-001
    Arezzo, 06156, Italy
  • Investigational Site Number 380-011
    Aviano, Italy
  • Investigational Site Number 380-025
    Bari, Italy
  • Investigational Site Number 380-007
    Bergamo, 24128, Italy
  • Investigational Site Number 380-015
    Bologna, Italy
  • Investigational Site Number 380-021
    Fano, Italy
  • Investigational Site Number 380-012
    Firenze, Italy
  • Investigational Site Number 380-003
    Genova, 16132, Italy
  • Investigational Site Number 380-005
    Genova, 16132, Italy
  • Investigational Site Number 380-014
    Lecce, Italy
  • Investigational Site Number 380-023
    Messina, Italy
  • Investigational Site Number 380-018
    Milano, Italy
  • Investigational Site Number 380-022
    Milano, Italy
  • Investigational Site Number 380-006
    Napoli, 80131, Italy
  • Investigational Site Number 380-010
    Napoli, 80131, Italy
  • Investigational Site Number 380-027
    Napoli, Italy
  • Investigational Site Number 380-004
    Orbassano, 10043, Italy
  • Investigational Site Number 380-017
    Padova, Italy
  • Investigational Site Number 380-002
    Parma, 43100, Italy
  • Investigational Site Number 380-009
    Roma, 00152, Italy
  • Investigational Site Number 380-008
    Roma, 00189, Italy
  • Investigational Site Number 380-024
    Rozzano, 20089, Italy
  • Investigational Site Number 380-020
    San Giovanni Rotondo, Italy
  • Investigational Site Number 380-013
    Sassari, Italy
  • Investigational Site Number 380-016
    Taormina, Italy
  • Investigational Site Number 398001
    Almaty, Kazakhstan
  • Investigational Site Number 398003
    Shymkent, Kazakhstan
  • Investigational Site Number 442001
    Niederkorn, 4602, Luxembourg
  • Investigational Site Number 458002
    Georgetown, 10050, Malaysia
  • Investigational Site Number 458001
    Kuala Lumpur, 59100, Malaysia

Showing the first 100 of 165 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, James ND, Mason MD, Kumar S, Bottomley D, Lydon A, Chowdhury S, Wylie J, de Bono JS. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 2015 Dec;116(6):880-7. doi: 10.1111/bju.13069. Epub 2015 Jun 16. PubMed 25639506 ↗
  • Castellano D, Anton Aparicio LM, Esteban E, Sanchez-Hernandez A, Germa JR, Batista N, Maroto P, Perez-Valderrama B, Luque R, Mendez-Vidal MJ; cabazitaxel EAP study. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opin Drug Saf. 2014 Sep;13(9):1165-73. doi: 10.1517/14740338.2014.939583. Epub 2014 Jul 7. PubMed 25001524 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2010
First posted
Dec 6, 2010
Start
Dec 2010
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Jan 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01254279
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Dec 2010
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Jan 21, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion